AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
2002 AUG 1 - (NewsRx.com & NewsRx.net) -- Immunomedics, Inc., (IMMU) announced that a presentation at the 49th annual meeting of the Society of Nuclear Medicine reported on the progress of a new antibody-based therapeutic in animals with transplanted human breast cancer.
This preclinical study evaluated an antibody known as humanized RS7 (hRS7) that targets breast, lung, prostate, and ovarian cancers, identifying a tumor-associated molecule named "epithelial glycoprotein-1."
In this study, the hRS7 antibody was labeled with iodine-131 (I-131) using the company's recently patented method that improves the length of time the I-131 stays attached to the antibody. This new labeling method resulted in 4-times the dose of I-131 delivered to the tumor, as compared with the same antibody labeled with I-131 using conventional methods. Increased exposure of the tumor to the I-131 resulted in 75% of the animals being cured.
"We believe this is a ...
Source: HighBeam Research, Preclinical progress reported at the Society of Nuclear Medicine...